Skip to content

Breast cancer staging

Last updated: 28 May 2024
1/2
  1. Breast cancer staging
  2. The TNM staging system for breast cancer
Breast cancer staging

Breast cancer staging

Cancer is staged using the TNM system. This calculates how advanced a cancer is by evaluating anatomic factors that can help determine the likely prognosis and appropriate treatment plan.

T refers to tumour size. Small tumours are less likely to have spread beyond the breast, resulting in better outcomes for treatment. Small tumours are generally classified as 20mm or less. N refers to the lymph node status (the number and location of cancerous lymph nodes). If any contain cancer cells, they are called positive nodes. M refers to the presence or absence of metastases.

Other factors, such as tumour grade, hormone receptor expression, HER2 over-expression and the results of any genomic testing, can also affect cancer staging.

The staging scale ranges from stage O to stage IV, where a higher stage indicates more advanced cancer. The chart below gives a summary of TNM staging:

The TNM staging system for breast cancer

Stage Tumour size Axillary lymph nodes Metastasis
0 (in situ) Cluster of cancer cells in a breast duct (in situ) No spread None
I Up to 2cm No spread None
II Smaller than 2cm Spread to axillary lymph nodes None
Between 2-5cm May or may not have spread to axillary lypmh nodes None
Larger than 5cm No spread None
III Any size Has spread to multiple axillary lymph ndoes so that the nodes have become attached to each
other
None
Larger than 5cm Has spread to axillary lymph nodes None
Any size but cells have spread to skin or chest wall May or may not have spread to axillary lypmh nodes None
Any size Has spread to lymph nodes along breastbone and above/below collarbone None
IV Any size May or may not have spread to axillary lypmh nodes Has spread to other organs of the body or the skin and lymph nodes about the collarbone

Bibliography

  • Koh J, Kim MJ. Introduction of a New Staging System of Breast Cancer for Radiologists: An Emphasis on the Prognostic Stage. Korean J Radiol. 2019;20(1):69-82. doi:10.3348/kjr.2018.0231 Journal
  • Lawrenson R, Lao C, Camppbell I, Harvey V, Seneviratne S, Elwood M, Sarfati D, Kuper-Hommel M. The impact of different tumour subtypes on management and survival of New Zealand women with Stage I-III breast cancer. NZMJ. 2018;131(1475):51-60.
  • Seneviratne S, Lawrenson R, Harvey V, Ramsaroop R, Elwood M, Scott N, Sarfati D, Campbell I. Stage of breast cancer at diagnosis in New Zealand: impacts of socio-demographic factors, breast cancer screening and biology. BMC Cancer. 2016;16:129. doi: 10.1186/s12885-016-2177-5.
  • Van Belle V et al. Qualitative Assessment of the Progesterone Receptor and HER2 Improves the Nottingham Prognostic Index Up to 5 Years After Breast Cancer Diagnosis. Journal of Clinical Oncology. 2010; 28(27): 4129-4134. doi: 10.1200/JCO.2009.26.4200.
  • Weston MK, Moss DP, Stewart J, Hill AG. Differences in breast cancer biological characteristics between ethnic groups in New Zealand. Breast Cancer Res Treat. 2008;111(3):555-8. doi: 10.1007/s10549-007-9813-3.

Was this article helpful?

Suggest an edit

Suggest an edit

Would additional content be helpful on this page? Email suggestions and feedback to intouch@bcf.org.nz. Thank you.

This field is optional
(e.g.+6421 000 0000)